[THE INVESTOR] Samsung BioLogics’ stock price already reflects its long-term growth potential and at 178 times its price-earnings ratio, it has little room to rise further, said KB Investment and Securities on March 6.
The securities firm suggested a “hold” recommendation and 380,000 won (US$353.16) target price, 18.4 percent lower than the current stock price.
The bio company went public in November and has leapt to fifth spot in terms of total market value at 30.8 trillion won, noted analyst Seo Geun-heui.
It will maintain its earnings momentum as operation ratios of its first and second factory rise, and by 2021 when the ratio of its third factory reaches as high as 89 percent, its total revenue will top 1.68 trillion won, estimated the analyst.
By Hwang You-mee (firstname.lastname@example.org)